Table 1. Risk factors for melioidosis, lesion locations, and treatment drugs in the central nervous system melioidosis patients.
| n/N (%)a | |
|---|---|
| Risk factorb | |
| Diabetes mellitus | 33/76 (43) |
| Excessive alcohol use | 14/63 (22) |
| Chronic lung disease | 1/16 (6) |
| Chronic kidney disease | 2/59 (3) |
| Kava drinking | 5/13 (38) |
| No risk factor | 34/84 (40) |
| Lesion locationc | |
| Frontal lobe | 23/68 (34) |
| Parietal lobe | 22/67 (33) |
| Temporal lobe | 9/68 (13) |
| Occipital lobe | 7/67 (10) |
| Brainstem | 22/65 (34) |
| Cerebellum | 15/65 (23) |
| Treatment drug | |
| Intensive phase | |
| Ceftazidime | 51/95 (54) |
| Trimethoprim/ sulfamethoxazole | 39/95 (41) |
| Meropenem | 32/91 (36) |
| Chloramphenicol | 12/95 (13) |
| Imipenem | 7/95 (7) |
| Doxycycline | 5/95 (5) |
| Others | 14/95 (15) |
| Eradication phase | |
| Trimethoprim/ sulfamethoxazole | 54/74 (73) |
| Doxycycline | 20/74 (27) |
| Amoxicillin/ clavulanic acid | 9/74 (12) |
| Others | 5/74 (7) |
a n is the number of patients in which the data was present, while N is the total number of patients for which that particular data was reported
b Data for excessive alcohol use, chronic lung disease and chronic kidney disease, which were reported in the publication, were not defined by its author.
c Lesion locations were determined by neuroimaging and presented only for the encephalomyelitis and brain abscess types.